June 2018

2018-06-01

PolTREG has been awarded 2 500 000 Euro grant in Horizon2020 in the healthcare biotechnology sector.(project 830559 – TREG: TREG – innovative cell therapy targeting Diabetes Type 1). We are the only Polish SME company that received support in this instrument in the area of healthcare. The money will be spent on the preparations to phase III clinical trial in type 1 diabetes.

https://www.kpk.gov.pl/?p=44366
http://ec.europa.eu/research/participants/portal/doc/call/h2020/eic-smeinst-2018-2020/1830105-eic_ph2_05-2018_en.pdf

See other news

2024-09-26

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

See

2024-09-16

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

See

2024-09-11

Join us for the PolTREG H1 2024 financial results webinar!

See

2024-09-09

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

See

2024-07-24

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.

See

2024-06-25

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

See

2024-06-24

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

See

2024-06-13

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

See

June 2018

See other news

About Us

Our Science

Patients